newsfilter
← Latest News
GlobeNewswire·

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in